Home / Market News / $NUVB
fiscal.ai Corporate Catalyst Impact 55/100 ● neutral

Wall Street Analysts Update Ratings and Price Targets for Nuvation Bio

Nov 7, 2026, 2:04 PM UTC · Primary ticker $NUVB

This filing discloses that several Wall Street analysts updated their coverage on Nuvation Bio, with RBC Capital Markets and B. Riley Securities lowering their price targets while maintaining 'Buy' ratings. Wedbush and H.C. Wainwright maintained both their 'Buy' ratings and existing price targets. This indicates a mixed but generally positive sentiment from analysts, with some slight downward adjustments to valuation expectations.

On November 6, 2026, Nuvation Bio (NUVB) received updated analyst coverage from four firms. While all maintained 'Buy' ratings, RBC Capital Markets and B. Riley Securities slightly lowered their price targets, from $20 to $17 and $14 to $13 respectively. Wedbush and H.C. Wainwright kept their targets unchanged at $11 and $21. This event is moderately impactful as it reflects ongoing analyst sentiment and valuation adjustments for NUVB. For traders, the short-term implication is a potential for minor price fluctuations based on these revised targets, though the maintained 'Buy' ratings suggest continued long-term confidence. The key risk is that the downward target revisions, even if slight, could signal a more cautious outlook on the company's near-term prospects or valuation.

$NUVB neutral Analyst coverage updates with mixed price target adjustments
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.